Vitiligo: What's old, what's new

Area of Science:

• Dermatology
• Immunology
• Pathobiology

Background:

• Vitiligo affects 0.5-2% of the global population, presenting a complex and unpredictable course.
• Recent evidence suggests vitiligo is an autoimmune condition involving T CD8+ cells and oxidative stress.
• The disease significantly impacts patients' quality of life, necessitating effective treatment strategies.

Purpose of the Study:

• To review current therapeutic options for vitiligo in adults and children.
• To analyze the recurrence rates associated with various vitiligo treatments.
• To highlight the goals of dermatologists in managing vitiligo patients.

Main Methods:

• Literature review of existing medical and surgical therapeutic options for vitiligo.
• Analysis of factors influencing treatment choices, including patient age and disease type.
• Examination of treatment outcomes, focusing on disease stabilization and repigmentation persistence.

Main Results:

• No definitive cure for vitiligo currently exists.
• Treatment selection depends on patient-specific factors and disease characteristics.
• Long-term repigmentation persistence is unpredictable, and recurrence rates vary among therapies.

Conclusions:

• Vitiligo management requires a multifaceted approach considering disease stability, patient factors, and psychological impact.
• Ongoing research is crucial for developing more predictable and persistent treatment outcomes.
• Understanding recurrence patterns is key to optimizing long-term vitiligo patient care.